Halofantrine

Mechanism :

Halofantrine, a phenanthrene methanol, is a blood schizonticide that is active against all malaria parasites. It is active against P. falciparum infections that are resistant to chloroquine and to sulfa drug-pyrimethamine combinations.

Indication :

Malaria, especially as a part of artemisinin combination therapy (ACT).

Contraindications :

The use of halofantrine is contraindicated in persons with a history of allergy to the drug, with pre-existing cardiac disease, with a family history of sudden death or of congenital prolongation of the QTc interval, who are using other drugs or have a clinical condition known to prolong the QTc interval, who have received treatment with mefloquine in the previous 3 weeks, pregnant women, breastfeeding mothers and children under one year.

Dosing :

Not recommended in children of <10 kg as data is insufficient.

>10 kg:

8 mg/kg/day PO in 3 divided doses every six hours.

Adverse Effect :

Diarrhea, abdominal pain, vomiting, headache, pruritus, elevated liver enzymes, rash, myalgia, back pain, rigors, QT prolongation.

Interaction :

Not known.

Hepatic Dose :

There are no dosage adjustments provided in the manufacturer's labeling; however, half-life may be prolonged and plasma levels may be higher in patients with hepatic impairment; use with caution.